Mgi Pharma — UBS Global Life Sciences Conference 2006
29 slides from Mgi Pharma's conference presentation, Sep 26, 2006
Slide 1: MGI PHARMA, INC. UBS Global Life Sciences Conference
MGI PHARMA, INC. UBS Global Life Sciences Conference September 26, 2006
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including those described in the Company's Annual Report for the year ended December 31, 2005 filed on Form 10-K, and most recent Quarterly Report filed on Form 10-Q.
Slide 3: MGI PHARMA Today
Biopharmaceutical company focused in oncology & acute care Two strong brand franchises supported by an experienced sales force Late stage pipeline provides excellent risk / reward profile Focus offers potential for significant business model leverage MDS - Launched (2Q 2006) AML - Phase 2, 3 CML - P
Slide 4: Significant Market Opportunities in Oncology & Acute Care
Product Potential Peak Sales Significant Market Opportunities in Oncology & Acute Care post-operative nausea & vomiting (PONV) $250M MDS $250M AML oral mucositis $100M sedation $250M chemotherapy-induced nausea & vomiting (CINV) $500M Indication
Slide 5: Agenda
Agenda Brand Franchises Complementary Late Stage Opportunities Near Term Milestones Financial Outlook Company Overview
Slide 6: Dacogen for Injection: FDA Approved 5/2/06
Dacogen(tm) for Injection: FDA Approved 5/2/06 U.S. peak sales potential >$250M Injectable hypomethylating agent Approved for treatment of patients with myelodysplastic syndromes (MDS) Broad product label U.S. launch underway Run rate exceeding 1,000 vials / week 80%+ Medicare coverage to date Subst
Slide 7: Substantial Market Opportunity in MDS
Substantial Market Opportunity in MDS ~20,000 MDS patient treatments per month 70%+ treated with supportive care Manages disease symptoms but does not impact underlying disease 10,000+ "aggressive MDS" patient treatments per month High risk, Int-2, & Int-1 with certain risk factors Dacogen offers pa
Slide 8: 5-Day Dosing Regimen Routinely Reimbursed
5-Day Dosing Regimen Routinely Reimbursed >70%
Slide 9: Building a Dacogen Brand Franchise
Building a Dacogen(tm) Brand Franchise Solid Tumors Myelodysplastic Syndromes (MDS) Acute Myeloid Leukemia (AML) MARKET Chronic Myelogenous Leukemia (CML) Alternative Dacogen OutPatient Treatment ("ADOPT" for MDS) PHASE 3 PHASE 2 PHASE 1 PRECLINICAL DACOGEN(tm) Excellent Risk / Reward Profile
Slide 10: Aloxi for CINV: Best-In-Class
Aloxi(r) for CINV: Best-In-Class Injectable serotonin subtype-3 (5-HT3) receptor antagonist (RA) Only 5-HT3 RA approved for the prevention of both acute & delayed CINV Superior efficacy demonstrated in clinical trials Market leading position: 33% Day 1 share 12% hospital & 46% clinic (Q2) Large mark
Slide 11: Balancing the Long-Term and the Short-Term
Balancing the Long-Term and the Short-Term Superior product profile Acute & delayed indication Market leadership position Dominant share of voice New indications & formulations Building patient loyalty (DTC campaign) Pharmacoeconomic benefit IP protection through 2015 Generic ondansetron Authorized
Slide 12: Aloxi Injection: Competitive Advantages Drive Growth
Aloxi Injection: Competitive Advantages Drive Growth Approved for both for acute and delayed CINV Single IV dose can protect a patient for up to 5 days Strong receptor binding and long half-life Top priority product Result: #1 market share in just 2 years Yes Yes Yes Yes Other Products No No No No S
Slide 13: Data Supports Use in More Emetogenic Regimens
Data Supports Use in "More Emetogenic" Regimens Palonosetron vs Ondansetron or Dolasetron in Chemo Naive Breast Cancer AC Subset - Acute Emesis and Nausea Prevention p=0.0132 p=0.0002 62.6 72.5 47.0 50.0 0 20 40 60 80 100 Complete Response Emesis-Free Acute: 0-24 hr (Day 1) % of Patients Palonosetro
Slide 14: Significant Opportunity Remains in More Emetogenic Regimen Segment
Significant Opportunity Remains in "More Emetogenic" Regimen Segment Overall CINV market weighted toward "more emetogenic" regimens Breast, lung, ovarian, colorectal cancers 60% "More Emetogenic" Regimens 40% "Less Emetogenic" Regimens 9% 24% 33% overall share Aloxi is used most often in "more emeto
Slide 15: Aloxi Injection for PONV Opportunity
Aloxi(r) Injection for PONV Opportunity Prevention of post-operative nausea & vomiting May provide similar advantages as to CINV patients Longer activity, better efficacy Broadens hospital market penetration Large market opportunity 30 million doses annually Status Phase 3 studies to complete 4Q06 F
Slide 16: Building an Aloxi Brand Franchise
Building an Aloxi(r) Brand Franchise Chemotherapy-Induced Nausea and Vomiting (CINV) Post-Operative Nausea and Vomiting (PONV) MARKETED Oral Formulation Capsule (CINV) PHASE 3 PHASE 2 PHASE 1 PRECLINICAL Aloxi(r) Excellent Risk/Reward Profile
Slide 17: Agenda
Agenda Brand Franchises Complementary Late Stage Opportunities Near Term Milestones Financial Outlook Company Overview
Slide 18: Aquavan Injection: Significant Opportunity
Aquavan(r) Injection: Significant Opportunity Opportunity Sedative for short duration procedures Profile may enable more rapid, clear-headed recovery without the need for monitored anesthesia care (MAC) Large market opportunity without competition Leverages acute care commercial team Status Pivotal
Slide 19: Aquavan Pivotal Program
Aquavan(r) Pivotal Program - -5 min 0 min 4 min 8 min 12 min Fentanyl Pretreatment Study Drug Initial Bolus Supplemental doses administered as needed for initiation & maintenance 300 patients Routine checkup 6.5 mg vs. 2.0 mg Aquavan; midazolam safety reference Colonoscopy 250 patients Diagnostic to
Slide 20: Strong Results From Pivotal Phase Colonoscopy Trial
Strong Results From Pivotal Phase 3 Colonoscopy Trial Primary endpoint achieved p<0.001 for Aquavan 6.5 mg/kg arm vs. Aquavan 2.0 mg/kg arm in sedation success p=0.002 for Aquavan 6.5 mg/kg arm vs. midazolam arm in sedation success Solid safety profile 1 case of hypoxia in a patient who received Aqu
Slide 21: Saforis Powder for Oral Suspension: Unmet Need Opportunity
Saforis(tm) Powder for Oral Suspension: Unmet Need Opportunity Prevention and treatment of oral mucositis No FDA approved therapeutic for non-BMT patients 200,000 patients annually in U.S. Status Successful pivotal phase 3 trial completed PDUFA goal date of October 12 (priority review) Strong additi
Slide 22: Summary: Robust Development Pipeline
Summary: Robust Development Pipeline Preclinical Phase 1 Phase 2 Phase 3 Regulatory Review Saforis (oral mucositis) Aquavan Injection (sedation) Aloxi Injection (PONV) Aloxi Oral Capsule (CINV) Amolimogene (cervical dysplasia) Dacogen for Injection (AML) Dacogen for Injection (MDS) Dacogen for Injec
Slide 23: Agenda
Agenda Brand Franchises Complementary Late Stage Opportunities Near Term Milestones Financial Outlook Company Overview
Slide 24: 2006 Guidance (Provided July 19, 2006)
($M) 2006 Guidance (Provided July 19, 2006) Pro Forma To GAAP Reconciling Items: SNDC Expenses ($4.2 million) Product Acquisition Intangible Asset Amortization ($10 million) Product Milestones ($2 million) Stock Option Expense under FASB 123R ($8-$10 million) Revenues $330-$350 COGS $125-130 SG&A $1
Slide 25: Looking Ahead
Looking Ahead 2006: $200 M Aloxi sales for 1st 9 months Disruption in CINV market expected to begin in Q4 2007: Achievable revenue forecast Growth rate expected to temporarily moderate Transient Aloxi market disruption expected in 1H07; offset by full year of Dacogen sales Growth resumes in 2H07; si
Slide 26: Agenda
Agenda Brand Franchises Complementary Late Stage Opportunities Near Term Milestones Financial Outlook Company Overview
Slide 27: Significant, Near Term Milestones
Significant, Near Term Milestones Maximize our brand franchises Complete Aloxi PONV pivotal program 4Q06 Complete Aloxi oral capsule pivotal program 4Q06 Advance the Dacogen pivotal AML program Advance our late stage pipeline Saforis PDUFA date of October 12 Complete enrollment in Aquavan pivotal pr
Slide 28: MGI PHARMA Today
Biopharmaceutical company focused in oncology & acute care Two strong brand franchises supported by an experienced sales force Late stage pipeline provides excellent risk / reward profile Focus offers potential for significant business model leverage MDS - Launched (2Q 2006) AML - Phase 2, 3 CML - P
Slide 29: MGI PHARMA, INC. UBS Global Life Sciences Conference
MGI PHARMA, INC. UBS Global Life Sciences Conference September 26, 2006
MGI Pharma — UBS Global Life Sciences Conference 2006 on 6ix